Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 3451 to 3500 of 3807 results for treatment

  1. Insertion of customised exposed titanium implants, without soft tissue cover, for complex orofacial reconstruction (HTG313)

    Evidence-based recommendations on insertion of customised exposed titanium implants, without soft tissue cover, for complex orofacial reconstruction. This involves making the titanium implants specially to fit the person using a model of their face.

  2. Lumbar infusion test for the investigation of normal pressure hydrocephalus (HTG169)

    Evidence-based recommendations on the lumbar infusion test for the investigation of normal pressure hydrocephalus. This involves inserting a lumbar needle into the spinal sac, recording the pressure of the CSF as fluid is infused into the sac.

  3. Thoracoscopic repair of congenital diaphragmatic hernia in neonates (HTG247)

    Evidence-based recommendations on thoracoscopic repair of congenital diaphragmatic hernia in neonates. This involves inserting surgical instruments through small cuts in the chest, and then moving the abdominal organs out of the chest and repairing the diaphragm.

  4. Digital technologies to support smoking cessation in secondary care patients: early value assessment

    In development Reference number: GID-HTE10061 Expected publication date: TBC

  5. PROPEL sinus implants for maintaining sinus patency after surgery (MIB253)

    NICE has developed a medtech innovation briefing (MIB) on PROPEL sinus implants for maintaining sinus patency after surgery .

  6. Sternal Talon for sternal closure in cardiothoracic surgery (MIB88)

    NICE has developed a medtech innovation briefing (MIB) on the Sternal Talon for sternal closure in cardiothoracic surgery .

  7. LATITUDE NXT Patient Management System for monitoring cardiac devices at home (MIB67)

    NICE has developed a medtech innovation briefing (MIB) on the LATITUDE NXT Patient Management System for monitoring cardiac devices at home

  8. NICE recommended that clinical data, including genotype and sustained virological response at 12 weeks, is collected for all people treated with sofosbuvir in the NHS.

    collect clinical data from people treated with the new generation of HCV treatments. NICE agreed that such efforts should be supported...

  9. MRI fusion biopsy systems for diagnosing prostate cancer (HTG678)

    Evidence-based recommendations on MRI fusion biopsy systems for diagnosing prostate cancer.

  10. Episcissors-60 for mediolateral episiotomy (HTG538)

    Evidence-based recommendations on Episcissors-60 for mediolateral episiotomy.

  11. Biotin for treating primary and secondary progressive multiple sclerosis [ID919]

    Discontinued Reference number: GID-TA10099

  12. Can vitamin D slow down the progression of disability in Multiple Sclerosis (MS)?

    after the onset of relapsing–remitting MS. While a variety of symptomatic treatments is available, progression in secondary progressive...

  13. Placement of pectus bar for pectus excavatum (also known as MIRPE or the Nuss procedure) (HTG199)

    Evidence-based recommendations on placement of pectus bar for pectus excavatum (Nuss procedure). This involves placing one or two steel (pectus) bars under the breastbone with the aim of raising it and correcting the abnormal shape.

  14. Percutaneous closure of patent foramen ovale for the secondary prevention of recurrent paradoxical embolism in divers (HTG243)

    Evidence-based recommendations on percutaneous closure of patent foramen ovale for the secondary prevention of recurrent paradoxical embolism in divers. This involves passing a device through a large vessel in the groin up into the heart and closing/blocking the hole in the wall.

  15. Science policy and methods projects

    Science policy projects with NICE.

  16. Abrocitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3768]

    Discontinued Reference number: GID-TA10764

  17. Vitamin D: supplement use in specific population groups (PH56)

    This guideline covers vitamin D supplement use. It aims to prevent vitamin D deficiency among specific population groups including infants and children aged under 4, pregnant and breastfeeding women, particularly teenagers and young women, people over 65, people who have low or no exposure to the sun and people with dark skin.

  18. ViewSite Brain Access System (VBAS) for the surgical management of deep brain lesions (MIB295)

    NICE has developed a medtech innovation briefing (MIB) on ViewSite Brain Access System (VBAS) for the surgical management of deep brain lesions .

  19. Short-term circulatory support with left ventricular assist devices as a bridge to cardiac transplantation or recovery (HTG115)

    Evidence-based recommendations on short-term circulatory support with left ventricular assist devices (LVAD) as a bridge to heart transplantation or recovery. This involves inserting a mechanical device into the chest to help the heart pump blood around the body.

  20. Endoscopic full thickness removal of non-lifting colonic polyps (HTG439)

    Evidence-based recommendations on endoscopic full thickness removal of non-lifting colonic polyps. This involves using a special device to remove the polyp and seal the bowel wall closed afterwards.

  21. How we develop technology appraisal guidance

    A step-by-step summary about how we develop our technology appraisal guidance.

  22. Juvenile idiopathic arthritis - abatacept [ID27]

    Discontinued Reference number: GID-TAG402

  23. ReStore Soft Exo-Suit for gait rehabilitation (MIB239)

    NICE has developed a medtech innovation briefing (MIB) on ReStore Soft Exo-Suit for gait rehabilitation .

  24. COVID-19 rapid guideline: delivery of systemic anticancer treatments (NG161)

    September 2023: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. For people with COVID-19 see our guideline on managing COVID-19

  25. Virtual chromoendoscopy to assess colorectal polyps during colonoscopy (HTG438)

    Evidence-based recommendations on virtual chromoendoscopy (VCE) using NBI, FICE or i-scan to assess colorectal polyps of 5 mm or less during colonoscopy.

  26. Aducanumab for treating mild cognitive impairment and mild dementia caused by Alzheimer's disease [ID3763]

    Discontinued Reference number: GID-TA10739

  27. ClearWay RX for drug delivery to coronary artery thrombotic lesions (MIB55)

    NICE has developed a medtech innovation briefing (MIB) on ClearWay RX for drug delivery to coronary artery thrombotic lesions

  28. What is the clinical and cost effectiveness of budesonide for treating COVID-19 in the community in adults, young people and children?

    for oxygen therapy (including thresholds for this decision)• Costs of treatment• Time to recovery• Health-related quality of life•...

  29. Datopotamab deruxtecan for treating advanced non-small-cell lung cancer after platinum-based chemotherapy [ID6241]

    Discontinued Reference number: GID-TA11277

  30. The social care guidance manual (PMG10)

    This manual explains how NICE develops and updates social care guidance. It provides advice on the technical aspects of guidance development and the methods used

  31. Transperineal biopsy for diagnosing prostate cancer (HTG680)

    Evidence-based recommendations on transperineal biopsy for diagnosing prostate cancer.

  32. YOURmeds for medication support in long-term conditions (MIB289)

    NICE has developed a medtech innovation briefing (MIB) on YOURmeds for medication support in long-term conditions .

  33. i STAT CG4+ and CHEM8+ cartridges for point-of-care testing in the emergency department (MIB38)

    NICE has developed a medtech innovation briefing (MIB) on i STAT CG4+ and CHEM8+ cartridges for point-of-care testing in the emergency department

  34. Behaviour change: individual approaches (PH49)

    This guideline covers changing health-damaging behaviours among people aged 16 and over using interventions such as goals and planning, feedback and monitoring, and social support. It aims to help tackle a range of behaviours including alcohol misuse, poor eating patterns, lack of physical activity, unsafe sexual behaviour and smoking.

  35. Tazemetostat for treating relapsed or refractory follicular lymphoma after 2 or more treatments [ID6349]

    Discontinued Reference number: GID-TA11399

  36. E-cigarette flavours: Do the flavours used in nicotine-containing e‑cigarettes have an impact on their effectiveness as an aid to stopping smoking, and are there any adverse effects associated with them?

    committee's discussion are in evidence review K: cessation and harm-reduction treatments. Source guidance details Comes from guidance...

  37. Use of e-cigarettes (amount and frequency): Does the effectiveness of nicotine-containing e‑cigarettes as an aid to stopping smoking vary according to the amount of nicotine they contain or the frequency of use?

    committee's discussion are in evidence review K: cessation and harm-reduction treatments. Source guidance details Comes from guidance...

  38. Active surveillance compared with surgery: For people with stage 1 differentiated thyroid cancer, what is the clinical and cost effectiveness of active surveillance compared with surgery?

    evidence and the committee's discussion are in evidence review H: initial treatments for differentiated thyroid cancer. Source guidance...

  39. What is the clinical and cost effectiveness of auto- and fixed-level continuous positive airway pressure (CPAP) for managing moderate and severe OSAHS?

    committee made the recommendation for research, see the rationale section on treatments for moderate and severe OSAHS . Full details of...

  40. Mandibular advancement splints for severe OSAHS: What is the clinical and cost effectiveness of mandibular advancement splints for managing severe OSAHS?

    committee made the recommendation for research, see the rationale section on treatments for moderate and severe OSAHS. Full details of...

  41. Better data for better decisions

    Sophie Cooper, senior scientific adviser in NICE’s science policy team, explains the importance of the recently published EQ-5D-5L value set and how it has the potential to help us decide if new treatments offer good value for money for the NHS.

  42. E-cigarettes for harm reduction: Are nicotine-containing e‑cigarettes effective and safe for harm reduction when used alongside tobacco products to cut down on smoking (dual-use approach)?

    committee's discussion are in evidence review K: cessation and harm-reduction treatments. Source guidance details Comes from guidance...

  43. Auto- versus fixed-level CPAP for OSAHS: What is the clinical and cost effectiveness of auto- and fixed-level continuous positive airway pressure (CPAP) for managing mild obstructive sleep apnoea/hypopnoea syndrome (OSAHS)?

    committee made the recommendation for research, see the rationale section on treatments for mild OSAHS . Full details of the evidence...

  44. Stop-smoking interventions for under-served groups: How can effective and cost-effective interventions to support people to stop smoking be modified to improve engagement with and accessibility for under-served groups? How acceptable are these interventions to these groups?

    committee's discussion are in evidence review K: cessation and harm-reduction treatments. Source guidance details Comes from guidance...

  45. Health effects of e-cigarettes: What are the short- and long-term health effects of e-cigarette use? Are there any specific health effects relating to use in pregnancy, or use by children and young people?

    discussion are in: - evidence review K: cessation and harm-reduction treatments - evidence review M: long-term health effects of...

  46. Analgesics:- What is the clinical and cost effectiveness of analgesic drugs other than non-steroidal antiinflammatory drugs (NSAIDs) in adults with rheumatoid arthritis (RA) whose pain or stiffness control is not adequate?

    opioids and compound analgesics) are sometimes used with disease-modifying treatments to relieve pain and stiffness when symptom control...

  47. Use of hearing aids and incidence of dementia:- In adults with hearing loss, does the use of hearing aids reduce the incidence of dementia?

    people with dementia, their families and the NHS, and there is no effective treatment to prevent its progression.Hearing loss is...